Skip to main content

NeoVax, a Personalized Neoantigen Cancer Vaccine, with or without Ipilimumab in Treating Patients with Stage III or IV Kidney Cancer

Trial Status: Active

This trial studies the best dose and side effects of ipilimumab and how well it works with or without NeoVax in treating patients with stage III or IV kidney carcinoma. Immunotherapy with monoclonal antibodies, such as ipilimumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. NeoVax is made of small protein fragments from a person's kidney cancer cells, called “peptides” and mixed with poly-ICLC (also called Hiltonol), which is an experimental “viral mimic” and an activator of immunity. Poly-ICLC binds proteins on the surface of certain immune cells to make it appear as if a virus is present. When the cells detect the vaccine, they think it is a virus and turn on the immune system. Giving booster vaccinations may make a stronger immune response and prevent or delay the recurrence of cancer. This trial is investigating how well neovax works with or without ipilimumab in treating kidney cancer.

Inclusion Criteria

  • INITIAL REGISTRATION: Ability to understand and the willingness to sign a written informed consent document before planned surgery.
  • INITIAL REGISTRATION: Patient should have suspected stage III or stage IV clear cell renal cell carcinoma (ccRCC), with anticipation that all disease can be surgically resected. Confirmation of clear cell histology, final stage (III or IV), and removal of all disease will be done after the surgery, and will be required for further participation in the trial.
  • INITIAL REGISTRATION: Patient is agreeable to allow tumor and normal tissue samples to be submitted for complete exome and transcriptome sequencing.
  • INITIAL REGISTRATION: Patients undergoing a potentially curative metastatectomy are eligible if the tumor tissue from the surgery is enough to make a vaccine.
  • INITIAL REGISTRATION: Eastern Cooperative Oncology Group (ECOG) performance status =< 1.
  • INITIAL REGISTRATION: Leukocytes >= 3,000/mcL.
  • INITIAL REGISTRATION: Absolute neutrophil count >= 1,500/mcL.
  • INITIAL REGISTRATION: Platelets >= 100,000/mcL.
  • INITIAL REGISTRATION: Total bilirubin within normal institutional limits.
  • INITIAL REGISTRATION: Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase [SGOT]) / alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 2.5 x institutional upper limit of normal.
  • INITIAL REGISTRATION: Creatinine clearance >= 25 mL/min (calculated using the Cockcroft-Gault equation).
  • INITIAL REGISTRATION: Women of childbearing potential (WOCBP) must have a negative pregnancy test (minimum sensitivity 25 IU/L or equivalent of human chorionic gonadotropin [HCG]) before entry onto the trial and within 7 days prior to start of study medication, because the effects NeoVax on the developing human fetus are unknown. It is the investigators’ responsibility to repeat the pregnancy test should start of treatment be delayed.
  • INITIAL REGISTRATION: Female patients enrolled in the study, who are not free from menses for > 2 years, post hysterectomy / oophorectomy, or surgically sterilized, must be willing to use either 2 adequate barrier methods or a barrier method plus a hormonal method of contraception to prevent pregnancy or to abstain from sexual activity for the duration of treatment with ipilimumab plus 5 half-lives of ipilimumab (75 days) plus 30 days (duration of ovulatory cycle) for a total of 105 days post-treatment completion. Approved contraceptive methods include for example: intra uterine device, diaphragm with spermicide, cervical cap with spermicide, male condoms, or female condom with spermicide. Spermicides alone are not an acceptable method of contraception.
  • INITIAL REGISTRATION: Male patients must agree to use an adequate method of contraception for the duration of treatment with study drugs plus 5 half-lives of the study drug (75 days) plus 90 days (duration of sperm turnover) for a total of 165 days post-treatment.
  • SECONDARY REGISTRATION: ECOG performance status =< 1.
  • SECONDARY REGISTRATION: Leukocytes >= 3,000/mcL.
  • SECONDARY REGISTRATION: Absolute neutrophil count >= 1,500/mcL.
  • SECONDARY REGISTRATION: Platelets >= 100,000/mcL.
  • SECONDARY REGISTRATION: Total bilirubin within normal institutional limits.
  • SECONDARY REGISTRATION: AST(SGOT)/ALT(SGPT) =< 2.5 x institutional upper limit of normal.
  • SECONDARY REGISTRATION: Creatinine clearance >= 25 mL/min (calculated using the Cockcroft-Gault equation).
  • SECONDARY REGISTRATION: Patients must have histologically confirmed clear cell renal cell carcinoma (ccRCC), stage III or fully resected stage IV (no evidence of disease), before starting study drugs per American Joint Committee on Cancer (AJCC) 8th edition.
  • SECONDARY REGISTRATION: No evidence of disease (NED) at secondary registration.
  • SECONDARY REGISTRATION: Women of childbearing potential (WOCBP) must have a negative pregnancy test (minimum sensitivity 25 IU/L or equivalent of HCG) within 7 days prior to start of study medication, because the effects NeoVax on the developing human fetus are unknown. It is the investigators’ responsibility to repeat the pregnancy test should start of treatment be delayed.
  • SECONDARY REGISTRATION: Female patients enrolled in the study, who are not free from menses for > 2 years, post hysterectomy / oophorectomy, or surgically sterilized, must be willing to use either 2 adequate barrier methods or a barrier method plus a hormonal method of contraception to prevent pregnancy or to abstain from sexual activity throughout the study, starting with visit 1 through 4 weeks after the last dose of study therapy. Approved contraceptive methods include for example; intra uterine device, diaphragm with spermicide, cervical cap with spermicide, male condoms, or female condom with spermicide. Spermicides alone are not an acceptable method of contraception.
  • SECONDARY REGISTRATION: Male patients must agree to use an adequate method of contraception for the duration of treatment with study drugs plus 5 half-lives of the study drug (75 days) plus 90 days (duration of sperm turnover) for a total of 165 days post-treatment.

Exclusion Criteria

  • Prior treatment with immune-modulatory agents including, but not limited to: IL-2, CTLA-4 blockade, PD-1/PD-L1 blockade, CD40 stimulation, or CD137 stimulation.
  • Prior investigational ccRCC-directed cancer vaccine therapy.
  • Patients with active brain metastases or leptomeningeal disease.
  • Prior systemic therapy, including targeted therapy such as VEGF or mTOR inhibitors unless it is > 6 months between last dose of drug and first vaccination with NeoVax. Systemic therapy is allowed only if prior therapy was not immune therapy (i.e. VEGF tyrosine kinase inhibitor [TKI]), and it was > 6 months ago.
  • Treatment with other investigational products within the last 2 months prior to entry into this study.
  • Previous bone marrow or stem cell transplant.
  • Concomitant therapy with any anti-cancer agents for ACTIVE cancer treatment, other investigational anti-cancer therapies, or immunosuppressive agents; chronic use of systemic corticosteroids with prednisone > 10 mg/day.
  • Use of a non-oncology vaccine therapy for prevention of infectious diseases is not allowed for 4 weeks prior to day 1, until 8 weeks after last study dose.
  • History of severe allergic reactions attributed to any vaccine therapy for the prevention of infectious diseases.
  • History of or current active autoimmune diseases, (e.g. including but not limited to inflammatory bowel diseases [IBD], rheumatoid arthritis, autoimmune thyroiditis, autoimmune hepatitis, systemic sclerosis [scleroderma and variants], systemic lupus erythematosus, autoimmune vasculitis, autoimmune neuropathies [such as Guillain-Barre syndrome]. Vitiligo and adequately controlled endocrine deficiencies such as hypothyroidism are not exclusionary.).
  • Patients who have had a history of acute diverticulitis, intra-abdominal abscess, gastrointestinal (GI) obstruction and abdominal carcinomatosis which are known risk factors for bowel perforation.
  • Concomitant treatment with corticosteroids greater than physiologic doses (used in the management of cancer or non-cancer-related illnesses). Topical (if not including the proposed vaccination sites) or inhalational steroids are allowed.
  • Known chronic infections with human immunodeficiency virus (HIV), hepatitis B or C. Serology results are not required for initial registration but they must be available before the start of vaccine production.
  • Uncontrolled intercurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia.
  • History of current immunodeficiency disease (e.g., splenectomy or splenic irradiation).
  • Any underlying medical condition, psychiatric condition or social situation that in the opinion of the investigator would compromise study administration as per protocol or compromise the assessment of adverse events (AEs).
  • Pregnant women are excluded from this study because personalized neoantigen peptides and poly-ICLC are agents with unknown risks to the developing fetus. Because there is an unknown but potential risk of adverse events in nursing infants secondary to treatment of the mother with personalized neoantigen peptides and poly-ICLC, nursing women are excluded from this study.
  • Individuals with a history of another invasive malignancy are ineligible except for the following circumstances: a) individuals with a history of invasive malignancy are eligible if they have been disease–free for at least 2 years and are deemed by the investigator to be at low risk for recurrence of that malignancy; b) individuals with any of the following cancers are eligible if diagnosed and treated: carcinoma in situ of the breast, oral cavity or cervix and basal cell or squamous cell carcinoma of the skin.

Massachusetts

Boston
Brigham and Women's Hospital
Status: ACTIVE
Contact: Toni K. Choueiri
Phone: 617-632-5456
Dana-Farber Cancer Institute
Status: ACTIVE
Contact: Toni K. Choueiri
Phone: 617-632-5456

PRIMARY OBJECTIVES:

I. To evaluate safety and tolerability of administering neoantigen-based renal cell carcinoma-poly-ICLC vaccine (NeoVax) and locally delivered ipilimumab in patients with fully resected, high-risk clear cell renal cell carcinoma (ccRCC).

II. To determine the maximum tolerated dose (MTD) of locally administered Ipilimumab when delivered with NeoVax.

SECONDARY OBJECTIVES:

I. To assess the induction of neoantigen-specific cellular immune responses following administration of NeoVax with Ipilimumab.

II. To determine the proportion of patients alive without recurrence at two years after surgery following administration of NeoVax with ipilimumab.

OUTLINE: This is a dose-escalation study of ipilimumab.

COHORT 1, COHORT 2, EXPANSION COHORT: Patients undergo surgery at week -10, then receive neoantigen-based renal cell carcinoma-poly-ICLC vaccine intradermally (ID) and subcutaneously (SC) and ipilimumab SC for up to 7 sets of 12 injections on days 1, 4, 8, 15, 22, 78, and 134.

COHORT 1B: Patients undergo surgery at week -10, then receive neoantigen-based renal cell carcinoma-poly-ICLC vaccine ID and SC for up to 7 sets of 8 injections on days 1, 4, 8, 15, 22, 78, and 134.

After completion of study treatment, patients are followed up every 3 months for a maximum of 2 years after surgery.

Trial Phase Phase I

Trial Type Treatment

Lead Organization
Dana-Farber Harvard Cancer Center

Principal Investigator
Toni K. Choueiri

  • Primary ID 16-097
  • Secondary IDs NCI-2019-02026
  • Clinicaltrials.gov ID NCT02950766